Marrow Cellution Iliac Crest Aspiration

Project Description

Product Description

The Marrow Cellution™ bone marrow aspiration device uses its patent(s) pending technology to harvest high quality stem & progenitor cells from various levels within the marrow space all while limiting peripheral blood contamination. Marrow Cellution™ uses a closed tip cannula to access the marrow space laterally, allowing marrow collection perpendicular to and around the channel created by the device. This ability to block the peripheral blood contamination eliminates the need to centrifuge the aspirate in order to obtain a high-quality autologous biologic.

The closed tip of the MARROW CELLUTIONTM trocar forces aspirate flow laterally, allowing marrow collection perpendicular to and around the channel created by the device.

Peripheral blood distal to the tip must access the cannula ports by pushing viscous marrow that is juxtaposed to the trocar’s side holes into the cannula.

MARROW CELLUTIONTM incorporates technology to precisely reposition the harvesting cannula within the marrow space after each aspiration.

Traditional Trocar Needles

A traditional trocar needle aspirates primarily peripheral blood that has little to no stem cells.

Marrow has a viscosity that is much greater than blood and resides in spongy tissue between the honeycomb structure of trabecular bone.

Only a finite number of stem cells reside in any single location in the marrow space.

Blood backfills any defect created in marrow.

Suction from the syringe creates the most force that is at the distal end of the cannula that is interfacing with a pool of blood created by the insertion of the needle.

The greatest force created by the syringe interfacing with the lower viscous tissue leads to excessive blood collection, requiring additional manipulation (i.e. centrifugation or chemical separation in a laboratory).

Key Benefits

Reduce the Cost of Utilizing Biologics

The Marrow CellutionTM System delivers a better regenerative solution (more stem cells) at a reduced cost compared to the industry leading solutions.

Minimize Sterility Challenges

Centrifugation systems require passing the BMA off the sterile field for processing and back on for implantation. The Marrow CellutionTM System eliminates the additional steps where infection concerns must be managed.

Minimize O/R Time

Centrifugation systems typically required 20 minutes or more of spin time during the surgical procedure, not to mention the additional personnel (perfusion) and support time needed for preparation and cleanup of the equipment.

Minimize Sample Waste

Centrifugation systems typically discard 80% of the aspirate due to the high levels of peripheral blood. Worse, significant numbers of the desired cells (approx. 40%) are discarded because as these cells increase in density prior to division, they are processed into the undesired red cell centrifuge component and thus discarded, substantially limiting the regenerative potential of the resulting sample.

Minimize Use of Anti-Coagulants

Centrifugation systems require at least 10% dilution by volume for the addition of anti-coagulant to allow the sample to separate, and also require another 10% dilution in the form of a neutralizing agent such as thrombin and calcium chloride in order for the marrow to clot in the graft. The Marrow CellutionTM System eliminates these requirements.

Eliminate the Need to Filter

Protocols require the marrow to be filtered prior to centrifugation. Cells bound within a cell aggregate can be delivered to the patient when mixed with graft material or injected. This is not the case when aggregates are filtered out prior to centrifugation. Filtering takes additional time, but more importantly, filtering reduces regenerative potential.

The Marrow CellutionTM aspiration system that incorporates a Single puncture promoting only Lateral flow from Multiple sites (SSLM Method) produced concentrations of CFU-fs, CD34+ cells and CD117+ cells that were comparable or greater compared directly to centrifuged bone marrow concentrates (BMAC) from the same patient.

Dr. Dan Kuebler Professor of Biology, Chair of the Biology Department; Franciscan University

A larger-volume of aspirate (more than 2mL) from a given site is contraindicated with the additional volume contributing little to the overall number of bone-marrow cells and results principally in unnecessary blood loss.